blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2744487

EP2744487 - NO- AND H2S- RELEASING COMPOUNDS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.08.2017
Database last updated on 24.08.2024
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Research Foundation of the City University of New York
230 West 41st Street
New York, NY 10036 / US
[N/P]
Former [2014/26]For all designated states
Research Foundation Of The City University Of New York
230 West 41st Street
New York, NY 10036 / US
Inventor(s)01 / KASHFI, Khosrow
City University of New York Medical School
Department of Physiology
Pharmacology and Neuroscience
Harris Hall, Suite 301, 138th Street&Convent Ave
New York, NY 10031 / US
02 / KODELA, Ravinder
City University of New York Medical School
Department of Physiology
Pharmacology and Neuroscience
Harris Hall, Suite 301, 138th Street&Convent Ave
New York, NY 10031 / US
 [2014/26]
Representative(s)V.O.
P.O. Box 87930
2508 DH Den Haag / NL
[2016/40]
Former [2014/26]Jansen, Cornelis Marinus
V.O.
Johan de Wittlaan 7
2517 JR Den Haag / NL
Application number, filing date12824542.015.08.2012
[2016/40]
WO2012US50922
Priority number, dateUS201161523513P15.08.2011         Original published format: US 201161523513 P
US201261615700P26.03.2012         Original published format: US 201261615700 P
US201261635624P19.04.2012         Original published format: US 201261635624 P
[2014/26]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2013025790
Date:21.02.2013
Language:EN
[2013/08]
Type: A2 Application without search report 
No.:EP2744487
Date:25.06.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 21.02.2013 takes the place of the publication of the European patent application.
[2014/26]
Type: B1 Patent specification 
No.:EP2744487
Date:05.10.2016
Language:EN
[2016/40]
Search report(s)International search report - published on:US10.05.2013
(Supplementary) European search report - dispatched on:EP27.01.2015
ClassificationIPC:A61K31/385, C07D339/04, A61P29/00
[2015/09]
CPC:
A61K31/655 (EP,US); C07C203/04 (US); A61P29/00 (EP);
C07C327/48 (US); C07C331/28 (US); C07D271/08 (US);
C07D339/04 (EP,US); C07D413/12 (US); C07F9/65583 (US);
C07F9/6578 (US) (-)
Former IPC [2014/26]A61K31/13, A01N33/24
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/26]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:NO- UND H2S-FREISETZENDE VERBINDUNGEN[2014/26]
English:NO- AND H2S- RELEASING COMPOUNDS[2014/26]
French:COMPOSÉS LIBÉRANT NO ET H2S[2014/26]
Entry into regional phase13.08.2013National basic fee paid 
13.08.2013Search fee paid 
13.08.2013Designation fee(s) paid 
13.08.2013Examination fee paid 
Examination procedure13.08.2013Examination requested  [2014/26]
13.07.2015Amendment by applicant (claims and/or description)
14.09.2015Despatch of a communication from the examining division (Time limit: M06)
19.02.2016Reply to a communication from the examining division
30.03.2016Despatch of a communication from the examining division (Time limit: M04)
04.05.2016Reply to a communication from the examining division
29.06.2016Communication of intention to grant the patent
06.07.2016Fee for grant paid
06.07.2016Fee for publishing/printing paid
06.07.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.09.2015
Opposition(s)06.07.2017No opposition filed within time limit [2017/37]
Fees paidRenewal fee
31.07.2014Renewal fee patent year 03
27.08.2015Renewal fee patent year 04
29.08.2016Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.08.2012
AL05.10.2016
AT05.10.2016
BE05.10.2016
CY05.10.2016
CZ05.10.2016
DK05.10.2016
EE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
IT05.10.2016
LT05.10.2016
LV05.10.2016
MC05.10.2016
MK05.10.2016
NL05.10.2016
PL05.10.2016
RO05.10.2016
RS05.10.2016
SE05.10.2016
SI05.10.2016
SK05.10.2016
SM05.10.2016
TR05.10.2016
BG05.01.2017
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
[2020/34]
Former [2020/15]HU15.08.2012
AT05.10.2016
BE05.10.2016
CY05.10.2016
CZ05.10.2016
DK05.10.2016
EE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
IT05.10.2016
LT05.10.2016
LV05.10.2016
MC05.10.2016
MK05.10.2016
NL05.10.2016
PL05.10.2016
RO05.10.2016
RS05.10.2016
SE05.10.2016
SI05.10.2016
SK05.10.2016
SM05.10.2016
TR05.10.2016
BG05.01.2017
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2019/51]HU15.08.2012
AT05.10.2016
BE05.10.2016
CY05.10.2016
CZ05.10.2016
DK05.10.2016
EE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
IT05.10.2016
LT05.10.2016
LV05.10.2016
MC05.10.2016
MK05.10.2016
NL05.10.2016
PL05.10.2016
RO05.10.2016
RS05.10.2016
SE05.10.2016
SI05.10.2016
SK05.10.2016
SM05.10.2016
BG05.01.2017
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2019/46]HU15.08.2012
AT05.10.2016
BE05.10.2016
CY05.10.2016
CZ05.10.2016
DK05.10.2016
EE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
IT05.10.2016
LT05.10.2016
LV05.10.2016
MC05.10.2016
NL05.10.2016
PL05.10.2016
RO05.10.2016
RS05.10.2016
SE05.10.2016
SI05.10.2016
SK05.10.2016
SM05.10.2016
BG05.01.2017
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2019/31]HU15.08.2012
AT05.10.2016
BE05.10.2016
CZ05.10.2016
DK05.10.2016
EE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
IT05.10.2016
LT05.10.2016
LV05.10.2016
MC05.10.2016
NL05.10.2016
PL05.10.2016
RO05.10.2016
RS05.10.2016
SE05.10.2016
SI05.10.2016
SK05.10.2016
SM05.10.2016
BG05.01.2017
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2018/18]AT05.10.2016
BE05.10.2016
CZ05.10.2016
DK05.10.2016
EE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
IT05.10.2016
LT05.10.2016
LV05.10.2016
MC05.10.2016
NL05.10.2016
PL05.10.2016
RO05.10.2016
RS05.10.2016
SE05.10.2016
SI05.10.2016
SK05.10.2016
SM05.10.2016
BG05.01.2017
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2017/52]AT05.10.2016
BE05.10.2016
CZ05.10.2016
DK05.10.2016
EE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
IT05.10.2016
LT05.10.2016
LV05.10.2016
NL05.10.2016
PL05.10.2016
RO05.10.2016
RS05.10.2016
SE05.10.2016
SI05.10.2016
SK05.10.2016
SM05.10.2016
BG05.01.2017
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2017/38]AT05.10.2016
BE05.10.2016
CZ05.10.2016
DK05.10.2016
EE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
IT05.10.2016
LT05.10.2016
LV05.10.2016
NL05.10.2016
PL05.10.2016
RO05.10.2016
RS05.10.2016
SE05.10.2016
SK05.10.2016
SM05.10.2016
BG05.01.2017
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2017/37]AT05.10.2016
BE05.10.2016
CZ05.10.2016
DK05.10.2016
EE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
IT05.10.2016
LT05.10.2016
LV05.10.2016
NL05.10.2016
PL05.10.2016
RO05.10.2016
RS05.10.2016
SE05.10.2016
SK05.10.2016
SM05.10.2016
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2017/36]AT05.10.2016
BE05.10.2016
CZ05.10.2016
DK05.10.2016
EE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
LT05.10.2016
LV05.10.2016
NL05.10.2016
PL05.10.2016
RO05.10.2016
RS05.10.2016
SE05.10.2016
SK05.10.2016
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2017/34]AT05.10.2016
BE05.10.2016
CZ05.10.2016
DK05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
LT05.10.2016
LV05.10.2016
NL05.10.2016
PL05.10.2016
RS05.10.2016
SE05.10.2016
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2017/33]AT05.10.2016
BE05.10.2016
DK05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
LT05.10.2016
LV05.10.2016
NL05.10.2016
PL05.10.2016
RS05.10.2016
SE05.10.2016
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2017/26]AT05.10.2016
BE05.10.2016
ES05.10.2016
FI05.10.2016
HR05.10.2016
LT05.10.2016
LV05.10.2016
NL05.10.2016
PL05.10.2016
RS05.10.2016
SE05.10.2016
NO05.01.2017
GR06.01.2017
IS05.02.2017
PT06.02.2017
Former [2017/12]LV05.10.2016
Documents cited:Search[I]WO2006111791  (CTG PHARMA S R L [IT], et al) [I] 1-20* page 6, line 5 - line 13; claims 1,4,5 *
International search[X]US2007275905  (WALLACE JOHN L [CA], et al);
 [Y]US2008293781  (GASCO ALBERTO [IT], et al);
 [Y]US2010210607  (WALLACE JOHN [CA], et al);
 [XP]  - CHATTOPADHYAY ET AL., "NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide- releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2012), vol. 419, pages 523 - 528, XP055136912

DOI:   http://dx.doi.org/10.1016/j.bbrc.2012.02.051
 [A]  - LAZZARATO ET AL., "New Nitric Oxide or Hydrogen Sulfide Releasing Aspirins.", J. MED. CHEM., 2011, (20110621), vol. 54, pages 5478 - 5484, XP055016631

DOI:   http://dx.doi.org/10.1021/jm2004514
by applicantWO2006111791
 US2007275905
    - "Anti-Inflammatory Agents as Cancer Therapeutics", K. KASHFI, Contemporary Aspects of Biomedical Research: Drug Discovery, Advances in Pharmacol, ELSEVIER, INC., (2009), vol. 57, pages 31 - 89
    - J. PHARM. SCI., (1977), vol. 66, page 2
    - WINTER ET AL., PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, (1962), vol. 111, pages 544 - 547
    - KODELA ET AL., ACS MED. CHEM. LETT., (2012), vol. 3, no. 3, pages 257 - 262
    - PENNING ET AL., J. MED. CHEM., (1997), vol. 40, pages 1347 - 1365
    - CHATTOPADHYAY ET AL., BIOCHEMICAL PHARMACOLOGY, (2012), vol. 83, no. 6, pages 715 - 722
    - KASHFI ET AL., J. PHARMACOL. EXP. THER., (2005), vol. 312, pages 978 - 988
    - BHATIA ET AL., FASEB. J., (2005), vol. 19, pages 1196 - 1198
    - HUANG ET AL., J. MOL. BIOL., (2010), vol. 396, pages 708 - 718
    - OLSON, BIOCHIM. BIOPHYS. ACTA, (2009), vol. 1787, pages 856 - 863
    - KULMACZ ET AL., PROSTAGLANDINS, (1983), vol. 25, pages 531 - 540
    - CHATTOPADHYAY ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2012), vol. 419, no. 3, pages 523 - 528
    - DELEON ET AL., ANAL. BIOCHEM., (2012), vol. 421, pages 203 - 207
    - MEADE ET AL., J. BIOL. CHEM., (1993), vol. 268, pages 6610 - 6614
    - RIENDEAU ET AL., CAN. J. PHYSIOL. PHARMACOL., (1997), vol. 75, pages 1088 - 1095
    - BEST R ET AL., BR J PHARMACOL, (1984), vol. 82, pages 107 - 116
    - CHATTOPADHYAY M ET AL., J PHARMACOL EXP THER., (2010), vol. 335, pages 443 - 50
    - LI L ET AL., FREE RADIO BIOL MED, (2007), vol. 42, pages 706 - 19
    - HUANG S ET AL., JMOL BIOL, (2010), vol. 396, pages 708 - 18
    - LEE ZW ET AL., PLOS ONE, (2011), vol. 6, no. 6, page E21077
    - PINTO L ET AL., PHARM PHARMACOL COMMUNICATION, (1988), vol. 4, pages 502 - 505
    - KULMACZ RJ ET AL., PROSTAGLANDINS, (1983), vol. 25, pages 531 - 540
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.